Lingua originale | Inglese |
---|---|
pagine (da-a) | 463-467 |
Numero di pagine | 5 |
Rivista | British Journal of Haematology |
Volume | 199 |
Numero di pubblicazione | 3 |
DOI | |
Stato di pubblicazione | Pubblicato - 2022 |
Keywords
- Antibodies, Viral
- COVID-19
- Hematologic Neoplasms
- Humans
- Immunity, Cellular
- Immunity, Humoral
- SARS-CoV-2
- Vaccination
- Vaccines
OSS delle Nazioni Unite
Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile
Accesso al documento
Altri file e collegamenti
Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: British Journal of Haematology, Vol. 199, N. 3, 2022, pag. 463-467.
Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review
TY - JOUR
T1 - Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients
AU - BORGOGNA, Cinzia
AU - Bruna, Riccardo
AU - Griffante, Gloria
AU - Martuscelli, Licia
AU - De Andrea, Marco
AU - FERRANTE, Daniela
AU - Patriarca, Andrea
AU - Mahmoud, Abdurraouf Mokhtar
AU - Ucciero, Maghalie Anais Marie
AU - Gaidano, Valentina
AU - Marchetti, Monia
AU - Rapezzi, Davide
AU - Lai, Michele
AU - Pistello, Mauro
AU - LADETTO, Marco
AU - Massaia, Massimo
AU - GAIDANO, Gianluca
AU - GARIGLIO, Marisa
N1 - Funding Information: This work was supported by Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy “Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies” (5 x 1000 No. 21198 to Gi.Ga.) and partially by the IG 21744 to Ma.Ma.; the AGING Project, Department of Excellence, DIMET, University of Piemonte Orientale, Novara, Italy to M.G. and Gi.Ga.; Ricerca Finalizzata 2018 (project RF‐2018‐12365790 to Gi.Ga.), MoH, Rome, Italy; Ministry for University ‐MUR‐ (PRIN 2017 to M.G., C.B. and M.P.; PRIN 2020 to M.G. and M.P.). We thank the UPO Biobank for its support for blood processing and storage. We are grateful to Sean P.J. Whelan for providing the rVSV‐SARS‐CoV‐2‐S. We acknowledge Associazione Italiana controle leucemie (AIL), Asti Alessandria and Regione Piemonte Bando INFRA‐P2: projects BSL3‐NTA (cod. 377‐4) and SURVEIL (cod. 378‐50). We thank Marcello Arsura for critically reviewing the manuscript. We acknowledge Operetta High Content Facility, CISUP, Centre for Instrumentation Sharing, University of Pisa. The authors thank Valeria Caneparo at CAAD, Center for Translational Research and Autoimmune and Allergic Disease,for assistance in the ELISA assay. Δ21 Funding Information: This work was supported by Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy “Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies” (5 x 1000 No. 21198 to Gi.Ga.) and partially by the IG 21744 to Ma.Ma.; the AGING Project, Department of Excellence, DIMET, University of Piemonte Orientale, Novara, Italy to M.G. and Gi.Ga.; Ricerca Finalizzata 2018 (project RF-2018-12365790 to Gi.Ga.), MoH, Rome, Italy; Ministry for University -MUR- (PRIN 2017 to M.G., C.B. and M.P.; PRIN 2020 to M.G. and M.P.). We thank the UPO Biobank for its support for blood processing and storage. We are grateful to Sean P.J. Whelan for providing the rVSV-SARS-CoV-2-SΔ21. We acknowledge Associazione Italiana controle leucemie (AIL), Asti Alessandria and Regione Piemonte Bando INFRA-P2: projects BSL3-NTA (cod. 377-4) and SURVEIL (cod. 378-50). We thank Marcello Arsura for critically reviewing the manuscript. We acknowledge Operetta High Content Facility, CISUP, Centre for Instrumentation Sharing, University of Pisa. The authors thank Valeria Caneparo at CAAD, Center for Translational Research and Autoimmune and Allergic Disease,for assistance in the ELISA assay.
PY - 2022
Y1 - 2022
KW - Antibodies, Viral
KW - COVID-19
KW - Hematologic Neoplasms
KW - Humans
KW - Immunity, Cellular
KW - Immunity, Humoral
KW - SARS-CoV-2
KW - Vaccination
KW - Vaccines
KW - Antibodies, Viral
KW - COVID-19
KW - Hematologic Neoplasms
KW - Humans
KW - Immunity, Cellular
KW - Immunity, Humoral
KW - SARS-CoV-2
KW - Vaccination
KW - Vaccines
UR - https://iris.uniupo.it/handle/11579/145480
U2 - 10.1111/bjh.18429
DO - 10.1111/bjh.18429
M3 - Article
SN - 1365-2141
VL - 199
SP - 463
EP - 467
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 3
ER -